Tag: Abzena
Abzena to Offer New, Integrated, Clinical Translation Service
Abzena, a life sciences company providing a series of specific serviced for the development of antibody-drug conjugates, earlier this week announced the launch of...
Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies
Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...
Abzena Completes Remodeling for New Antibody-drug Conjugate Manufacturing Facility
Abzena, a the life sciences company providing proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, including antibody-drug conjugates...
London Calling: The Cutting-edge of Novel ADC Technologies
Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...
Abzena Signs Major ThioBridge™ Agreement with US Biotech Partner
Earlier today, Abzena, a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announced that it had signed...
Antitope and Synthon Collaborate In Assessing the Potential Immunogenicity of Candidate...
Cambridge (UK) based Antitope, a subsidiary of Abzena, has signed an agreement to collaborate with Synthon Biopharmaceuticals, a global pharmaceutical company based in Nijmegen,...
